CEO SUMMARY: Some executives at pharmacogenetic testing companies are criticizing the federal Food and Drug Administration for its recent actions to exercise oversight over PGx testing. But there is more to the story, said one expert who is a past adviser to the FDA on clinical laboratory testing. One issue is how to educate physicians
Tag: diagnostics industry
CEO SUMMARY: After nearly two years of legal battles, Abbott Laboratories’ acquisition of Alere concluded on Oct. 3. Despite antitrust requirements to divest several of Alere’s diagnostic businesses to Quidel and Siemens Healthineers, the merger makes Abbott the world’s largest provider of point-of-care testing systems. Hospitals and clinical laboratories buying POC products from Abbott and
Last month, it was announced that Solstas Lab Partners of Greensboro, North Carolina, had agreed to be sold to Quest Diagnostics Incorporated. The sales price is $570 million and financial analysts on Wall Street estimate that the annual revenue at Solstas Lab Partners is about $350 million. This would indicate that Quest Diagnostics paid a
IN THE FINAL WEEKS OF 2013, the federal Centers for Medicare & Medicaid Services (CMS) announced that it would reduce the price it pays for the BRCA genetic test by 49%, to $1,438, effective on January 1, 2014.
For Myriad Genetics, Inc., this was not welcome news. Its share price fell by as much as 20%
CEO SUMMARY: Biggest deal in recent weeks was the $1.55 billion Beckman Coulter paid to acquire BioSite and its Triage BNP test. But the most interesting news may be the entry of 3M Corporation into clinical diagnostics, based on its acquisition of Acolyte Biomedica Ltd., a company which offers a five-hour rapid culture-based MRSA test.
CEO SUMMARY: It is a significant acquisition, and not just because Diagnostic Products Corporation has a major presence in immunodiagnostics. Siemens Medical Solutions is one of the dominant competitors in radiology. Its willingness to pony up almost $2 billion to enter the clinical diagnostics market signals a serious intent to develop services that support individualized
Its recent financial restructuring now complete, Dade Behring prepares a “brand building” campaign
CEO SUMMARY: Dade Behring is poised to become a tough and high-profile competitor in the laboratory diagnostics marketplace. Earlier this month, it finalized a major financial restructuring. Following two years of negotiations with its banks and bondholders, Dade filed a “pre-pack- aged” Chapter
CEO SUMMARY: In past years, it was customary for laboratories to shift away from performing or ordering “home brew” tests in favor of FDA-approved test kits as they became available. However, new marketing models for diagnostic testing are shifting this long-standing practice. HIV resistance testing is one type of testing where this battle between “home
CEO SUMMARY: Even as pressures to squeeze costs and consolidate within the pathology profession ease, a different set of market trends is exerting influence. Collectively, these trends portend the end of the small pathology group’s dominance of its local healthcare marketplace. It will become increasingly important for successful pathology groups to offer a full range
This section of the White Paper deals with the marketplace for laboratory services. For brevity and clarity, I will address five components: 1) independent commercial laboratories; 2) hospital-based laboratories; 3) esoteric, reference, and specialty testing laboratories; 4) anatomic pathology lab- oratories; and 5) diagnostics manufacturers and suppliers.
These groups represent the basic divisions within the competitive